Page 35 - 2021_12-Haematologica-web

Prognostic relevance of subclonal mutations in ALL
Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98(4):597-601.
33. Paulsson K, Lilljebjörn H, Biloglav A, et al. The genomic landscape of high hyper- diploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672-676.
34. Clappier E, Auclerc MF, Rapion J, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28(1):70-77.
35. Zaliova M, Potuckova E, Hovorkova L, et al. ERG deletions in childhood acute lym- phoblastic leukemia with DUX4 rearrange- ments are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. Haematologica. 2019;104(7):1407-1416.
36.Tzoneva G, Dieck CL, Oshima K, et al.
Clonal evolution mechanisms in NT5C2 mutant relapsed acute lymphoblastic leukemia. Nature. 2018;553(7689):511-514.
37. Meyer JA, Wang J, Hogan LE, et al. Relapse- specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013;45(3):290-294.
38. Pieters R, Huismans DR, Loonen AH, et al. Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in child- hood leukemia. Leuk Res. 1992; 16(9):873- 880.
39. Miller MS, Miller LD. RAS mutations and oncogenesis: not all RAS mutations are cre- ated equally. Front Genet. 2012;2:100.
40. Prior IA, Lewis PD, Mattos C. A comprehen- sive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457-2467.
41. Winters IP, Chiou S-H, Paulk NK, et al. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nat Commun. 2017;8(1):2053.
42. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015;5:8535.
43. Marke R, Havinga J, Cloos J, et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lym- phoblastic leukemia. Leukemia. 2016; 30(7):1599-1603.
44. Imamura T, Yano M, Asai D, et al. IKZF1 deletion is enriched in pediatric B-cell pre- cursor acute lymphoblastic leukemia patients showing prednisolone resistance. Leukemia. 2016;30(8):1801-1803.
45. Churchman ML, Low J, Qu C, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell. 2015;28(3):343-356.
46. van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014;123(11):1691-1698.
haematologica | 2021; 106(12)
3055